Home » Stocks » ChromaDex

ChromaDex Corporation (CDXC)

Stock Price: $4.80 USD -0.05 (-1.03%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 295.80M
Revenue (ttm) 54.77M
Net Income (ttm) -25.67M
Shares Out 61.62M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $4.80
Previous Close $4.85
Change ($) -0.05
Change (%) -1.03%
Day's Open 4.83
Day's Range 4.79 - 4.87
Day's Volume 148,316
52-Week Range 2.50 - 5.80

More Stats

Market Cap 295.80M
Enterprise Value 278.22M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 61.62M
Float 43.38M
EPS (basic) -0.43
EPS (diluted) -0.43
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.25M
Short Ratio 7.10
Short % of Float 4.49%
Beta 1.63
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.40
PB Ratio 13.62
Revenue 54.77M
Operating Income -25.33M
Net Income -25.67M
Free Cash Flow -15.69M
Net Cash 17.58M
Net Cash / Share 0.29
Gross Margin 47.05%
Operating Margin -46.24%
Profit Margin -46.90%
FCF Margin -28.64%
ROA -34.85%
ROE -139.78%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.10*
(47.92% upside)
Low
6.00
Current: $4.80
High
8.50
Target: 7.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue46.2931.5621.2021.6617.8815.3110.1611.618.117.57
Revenue Growth46.69%48.85%-2.14%21.13%16.79%50.71%-12.48%43.12%7.22%-
Gross Profit25.7716.0610.4810.397.535.333.132.282.472.94
Operating Income-31.30-33.24-16.38-2.91-2.07-5.19-4.34-11.64-7.86-2.02
Net Income-32.15-33.32-11.38-2.93-2.77-5.39-4.42-11.66-7.89-2.05
Shares Outstanding57.0655.0144.6037.2935.8835.4933.3330.0922.7716.08
Earnings Per Share-0.56-0.61-0.26-0.08-0.08-0.15-0.12-0.39-0.36-0.12
Operating Cash Flow-20.44-20.91-9.80-2.94-2.11-2.58-3.91-10.12-4.10-2.66
Capital Expenditures-0.74-1.32-1.17-1.50-0.53-0.12-0.14-0.02-0.15-0.17
Free Cash Flow-21.18-22.23-10.97-4.44-2.64-2.70-4.04-10.14-4.25-2.83
Cash & Equivalents18.8122.6245.662.025.614.022.260.550.462.26
Total Debt1.720.310.510.605.542.770.420.230.240.28
Net Cash / Debt17.0922.3145.161.420.071.251.840.330.221.98
Assets40.2542.2362.7219.7518.7511.528.999.036.276.51
Liabilities19.8015.058.899.7813.477.523.325.043.711.57
Book Value20.4527.1853.839.975.274.005.673.992.564.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ChromaDex Corporation
Country United States
Employees 110
CEO Robert N. Fried

Stock Information

Ticker Symbol CDXC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CDXC

Description

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.